Abbott Laboratories
NYSE:ABTMedical - Devices
-$0.51 today
- Market cap
- $180.95B
- Beta
- 0.62
- P/E (TTM)
- 24.5
- EPS (TTM)
- $3.59
- Dividend yield
- 2.77%
Volume 7.02M
Average 13.17M
ABT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Abbott LaboratoriesNYSE: ABT
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities remains negative
Q2 FY2026 other current liabilities was $0, compared with $6.69B a year earlier. Over 3 fiscal years it compounded at -5.2% a year.
Context
- Other current liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, down 8.0 pp from a year earlier.
- Other current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.54B USD
- Year-over-year change
- -6.4%
- 4-year CAGR
- -1.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.54B | -6.4% |
| FY2024 | 2024-12-31 | 5.91B | -3.6% |
| FY2023 | 2023-12-31 | 6.13B | -5.7% |
| FY2022 | 2022-12-31 | 6.5B | +12.7% |
| FY2021 | 2021-12-31 | 5.77B | — |
Other Current Liabilities vs competitors
How ABT compares with its peers on the latest reported figures
- ABT's Jun 2026 other current liabilities of $0 is the 8th highest of the 10 companies compared; the peer median is $1.43B.
- Its year-over-year change of -100.0% is the 7th highest of 9, against a peer median of +3.6%.
- Other current liabilities amounts to 0.0% of total assets for ABT, versus a peer median of 3.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $11.91B | — | — | 10.4% | |
| Jul 2026 | $5.51B | +173.4% | +11.2% | 5.9% | |
| Sep 2026 | $5.21B | +13.3% | +26.1% | 5.6% | |
| Jun 2026 | $2.6B | -6.0% | +5.3% | 5.4% | |
| Jun 2026 | $1.43B | +22.1% | +63.1% | 3.8% | |
| Jun 2026 | $732M | +22.6% | +9.8% | 1.6% | |
| Jun 2026 | $386.7M | -29.3% | +42.1% | 2.8% | |
| Jun 2026 | $0 | -100.0% | -5.2% | 0.0% | |
| Sep 2026 | $0 | -100.0% | -11.9% | 0.0% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding ABT) | $1.43B | +3.6% | +11.2% | 3.8% | |
Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.8B | 9.88B | 6.9B | 7.62B | 8.52B |
| Short-term Investments | 450M | 288M | 383M | 351M | 417M |
| Net Receivables | 6.49B | 6.22B | 6.57B | 6.93B | 7.93B |
| Inventory | 5.16B | 6.17B | 6.57B | 6.19B | 6.49B |
| Other Current Assets | 2.35B | 2.66B | 2.26B | 2.57B | 2.64B |
| Total Current Assets | 24.24B | 25.22B | 22.67B | 23.66B | 26B |
| Property, Plant & Equipment (Net) | 10.11B | 10.28B | 11.28B | 11.73B | 12.94B |
| Goodwill | 23.23B | 22.8B | 23.68B | 23.11B | 24.04B |
| Intangible Assets | 12.74B | 10.45B | 8.82B | 6.65B | 5.53B |
| Long-term Investments | 903M | 766M | 799M | 886M | 918M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.97B | 4.92B | 5.98B | 15.38B | 17.3B |
| Total Non-current Assets | 50.96B | 49.21B | 50.54B | 57.76B | 60.72B |
| Total Assets | 75.2B | 74.44B | 73.21B | 81.41B | 86.71B |
| Account Payables | 4.41B | 4.61B | 4.3B | 4.2B | 4.24B |
| Short-term Debt | 999M | 2.48B | 1.33B | 1.75B | 3.31B |
| Tax Payables | 306M | 343M | 492M | 594M | 569M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.77B | 6.5B | 6.13B | 5.91B | 5.54B |
| Total Current Liabilities | 13.11B | 15.49B | 13.84B | 14.16B | 16.5B |
| Long-term Debt | 17.3B | 14.52B | 13.6B | 12.63B | 10.83B |
| Deferred Tax Liabilities | 2.07B | 1.84B | 1.22B | 1.37B | 1.96B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.74B | 4.74B | 4.78B | 4.46B | 3.73B |
| Total Non-current Liabilities | 26.07B | 22.04B | 20.55B | 19.36B | 17.45B |
| Total Liabilities | 39.17B | 37.53B | 34.39B | 33.51B | 33.94B |
| Common Stock | 24.47B | 24.71B | 24.87B | 25.15B | 25.53B |
| Retained Earnings | 31.53B | 35.26B | 37.55B | 47.26B | 49.78B |
| Accumulated OCI | (8.37B) | (8.05B) | (7.84B) | (7.91B) | (6B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 222M | 219M | 224M | 237M | 641M |
| Total Equity | 36.02B | 36.91B | 38.83B | 47.9B | 52.77B |
| Total Debt | 19.25B | 17.95B | 15.87B | 15.28B | 15.07B |
| Net Debt | 9.45B | 8.06B | 8.98B | 7.66B | 6.55B |
Abbott Laboratories
NYSE:ABT
Intrinsic Alpha fair value
Locked
Current Price
$104.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.